Simtuzumab
- Generic Name
- Simtuzumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1318075-13-6
- Unique Ingredient Identifier
- 11Z5AIU653
- Background
Simtuzumab has been used in trials studying the treatment and basic science of Myelofibrosis, Pancreatic Cancer, Colorectal Cancer, and Idiopathic Pulmonary Fibrosis.
- Associated Conditions
- -
- Associated Therapies
- -
Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)
- Conditions
- Interventions
- First Posted Date
- 2013-01-16
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 544
- Registration Number
- NCT01769196
- Locations
- 🇺🇸
Sarasota Memorial Hospital, Sarasota, Florida, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2013-01-03
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 34
- Registration Number
- NCT01759511
- Locations
- 🇺🇸
Arizona Pulmonary Specialists, Ltd., Scottsdale, Arizona, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2015-03-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 250
- Registration Number
- NCT01472198
- Locations
- 🇺🇸
UCLA Community Oncology Practice, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States
Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
- First Posted Date
- 2011-06-09
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 54
- Registration Number
- NCT01369498
- Locations
- 🇺🇸
Stanford University Medical center, Stanford, California, United States
🇺🇸Oncology Hematology Care Clinical Trials, Cincinnati, Ohio, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2011-05-30
- Last Posted Date
- 2015-07-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 48
- Registration Number
- NCT01362231
- Locations
- 🇺🇸
Loess Hills Clinical Research Center, Council Bluffs, Iowa, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.